Literature DB >> 27894720

Polio vaccines: WHO position paper, March 2016-recommendations.

.   

Abstract

This article presents the World Health Organization's (WHO) recommendations on the use of polio vaccine excerpted from the WHO position paper on polio vaccines - March 2016, published in the Weekly Epidemiological Record [1]. This position paper on polio vaccines replaces the 2014 WHO position paper [2]. The position paper summarizes the WHO position on the introduction of at least one dose of inactivated polio vaccine (IPV) into routine immunization schedules as a strategy to mitigate the potential risk of re-emergence of type 2 polio following the withdrawal of Sabin type 2 strains from oral polio vaccine (OPV) [3]. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. This position paper reflects the global switch from trivalent to bivalent OPV which took place in April 2016. Recommendations on the use of polio vaccines have been discussed on multiple occasions by SAGE, most recently in October 2016; evidence presented at these meetings can be accessed at: http://www.who.int/immunization/sage/previous/en/index.html.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27894720     DOI: 10.1016/j.vaccine.2016.11.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010-2020.

Authors:  Anna N Chard; Maureen Martinez; Almea Matanock; Ahmed M Kassem
Journal:  Vaccine       Date:  2021-09-16       Impact factor: 4.169

Review 2.  Vaccines and Senior Travellers.

Authors:  Fiona Ecarnot; Stefania Maggi; Jean-Pierre Michel; Nicola Veronese; Andrea Rossanese
Journal:  Front Aging       Date:  2021-07-09

3.  Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication.

Authors:  Asghar Aghamohammadi; Hassan Abolhassani; Necil Kutukculer; Steve G Wassilak; Mark A Pallansch; Samantha Kluglein; Jessica Quinn; Roland W Sutter; Xiaochuan Wang; Ozden Sanal; Tatiana Latysheva; Aydan Ikinciogullari; Ewa Bernatowska; Irina A Tuzankina; Beatriz T Costa-Carvalho; Jose Luis Franco; Raz Somech; Elif Karakoc-Aydiner; Surjit Singh; Liliana Bezrodnik; Francisco J Espinosa-Rosales; Anna Shcherbina; Yu-Lung Lau; Shigeaki Nonoyama; Fred Modell; Vicki Modell; Mohamed-Ridha Barbouche; Mark A McKinlay
Journal:  Front Immunol       Date:  2017-06-13       Impact factor: 7.561

4.  Draft Genome Sequence of Salmonellaenterica Serovar Typhi IMR_TP298/15, a Strain with Intermediate Susceptibility to Ciprofloxacin, Isolated from a Typhoid Outbreak.

Authors:  Norazah Ahmad; Shirley Yi Fen Hii; Rohaidah Hashim; Rahizan Issa
Journal:  Genome Announc       Date:  2017-03-02

Review 5.  Neonatal Immunization: Rationale, Current State, and Future Prospects.

Authors:  Elizabeth Whittaker; David Goldblatt; Peter McIntyre; Ofer Levy
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

6.  Natural Clearance of Prolonged VDPV Infection in a Child With Primary Immunodeficiency Disorder.

Authors:  Madhu Chhanda Mohanty; Manisha Ranjan Madkaikar; Mukesh Desai; Jahnavi Aluri; Swapnil Yashwant Varose; Prasad Taur; Deepa Kailash Sharma; Uma Prajwal Nalavade; Sneha Vijay Rane; Maya Gupta; Snehal Shabarish; Aparna Dalvi; Jagadish Mohanrao Deshpande
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

7.  Immunity levels to poliovirus in Lao children and adults before the vaccine-derived poliovirus outbreak: A retrospective study.

Authors:  Maude Pauly; Antony P Black; Phonepaseuth Khampanisong; Phonethipsavanh Nouanthong; Judith M Hübschen; Naphavanh Nanthavong; Kong Sayasinh; Prapan Jutavijittum; Bounthome Samountry; Anonh Xeuatvongsa; Sabine Diedrich; Claude P Muller
Journal:  PLoS One       Date:  2018-05-15       Impact factor: 3.240

8.  Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.

Authors:  Woo-Jin Shin; Daiki Hara; Francisca Gbormittah; Hana Chang; Byeong S Chang; Jae U Jung
Journal:  MBio       Date:  2018-11-27       Impact factor: 7.867

9.  Antirotavirus IgA seroconversion rates in children who receive concomitant oral poliovirus vaccine: A secondary, pooled analysis of Phase II and III trial data from 33 countries.

Authors:  Julia M Baker; Jacqueline E Tate; Juan Leon; Michael J Haber; Benjamin A Lopman
Journal:  PLoS Med       Date:  2019-12-30       Impact factor: 11.069

10.  Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses.

Authors:  Siddhartha Kumar Bhaumik; Raveendra R Kulkarni; William C Weldon; Eduardo L V Silveira; Hasan Ahmed; Sivaram Gunisetty; Anmol Chandele; Rustom Antia; Harish Verma; Roland Sutter; Mark A Pallansch; M Steven Oberste; Francois Villinger; Walter Orenstein; Kaja Murali-Krishna
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.